ipilimumab,nivolumab
bms
['check,mate,914', 'rcc,(-irccs),(-srcc),(-urcc)', 'checkmate-914', 'bristol']
the checkmate-914 trial's disappointing results cast doubt on ' plans to advance pd-1 inhibitors in combination with ctla4 inhibitors into earlier-stage rcc. visit for more in-depth details: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry